These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21691803)

  • 1. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.
    Elkalioubie A; Allorge D; Robriquet L; Wiart JF; Garat A; Broly F; Fourrier F
    Eur J Clin Pharmacol; 2011 Aug; 67(8):855-8. PubMed ID: 21691803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
    Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
    Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
    Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
    Srinivas NR
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
    Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
    Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
    Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
    Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials.
    Zebala JA; Searle SL; Webster LR; Johnson MS; Schuler AD; Maeda DY; Kahn SJ
    J Pain; 2019 Oct; 20(10):1218-1235. PubMed ID: 31005596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
    Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
    Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
    Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
    Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
    Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
    Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
    J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
    Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.
    Allegaert K; Holford N; Anderson BJ; Holford S; Stuber F; Rochette A; Trocóniz IF; Beier H; de Hoon JN; Pedersen RS; Stamer U
    Clin Pharmacokinet; 2015 Feb; 54(2):167-78. PubMed ID: 25258277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantiomeric determination of tramadol and O-desmethyltramadol by liquid chromatography- mass spectrometry and application to postoperative patients receiving tramadol.
    Musshoff F; Madea B; Stuber F; Stamer UM
    J Anal Toxicol; 2006 Sep; 30(7):463-7. PubMed ID: 16959140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmortem redistribution of tramadol and O-desmethyltramadol.
    Costa I; Oliveira A; Guedes de Pinho P; Teixeira HM; Moreira R; Carvalho F; Dinis-Oliveira RJ
    J Anal Toxicol; 2013; 37(9):670-5. PubMed ID: 24084873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain.
    Noehr-Jensen L; Zwisler ST; Larsen F; Sindrup SH; Damkier P; Brosen K
    Clin Pharmacol Ther; 2009 Dec; 86(6):626-33. PubMed ID: 19710642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification in postmortem blood and identification in urine of tramadol and its two main metabolites in two cases of lethal tramadol intoxication.
    De Backer B; Renardy F; Denooz R; Charlier C
    J Anal Toxicol; 2010 Nov; 34(9):599-604. PubMed ID: 21073815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
    Gan SH; Ismail R; Wan Adnan WA; Zulmi W
    Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.